Skip to content
Mendelspod Podcast cover art

All episodes

Mendelspod Podcast, 582 episodes. Page 5 of 6.

#
Title
401

The Last Major Disease To Be Studied? Ron Davis of Stanford Thinks So

402

On Bioinformatics Data Sharing and Collaboration: Andrew Carroll, DNAnexus

403

Grail Merger, Genomic Autopsies, Overtreatment Alarm, and Controversy at Ancestry.com: May 2017 Review with Nathan and Laura

404

Is Population Medicine Failing Us? Michel Accad

405

Deep Omics Profiler, Mike Snyder, Now Turns to Wearables

406

Over $1 Billion Invested this Past Year: Synthetic Biology in 2017 with John Cumbers

407

Green Light for DTC, Blood Mammograms, and Ancient DNA: April 2017 with Nathan and Laura

408

With 50 Million Users, Is Academia.edu Speeding Up Science?

409

How to Improve Lab Tests in the Absence of FDA Regulation?

410

Known for Medical Devices, 116 Yr Old BD Makes a Bold Move in Genomics

411

Proposed NIH Cuts, Undermining GINA, and Game Changing Drugs: March 2017 with Nathan and Laura

412

Art in the Lab (Falling in Love with Bacteria)

413

Flint Whistleblower Says Today's Science Is to Blame for Its Own Lack of Public Trust

414

The Story of Geisinger and Doing Genomic Medicine at the Right Pace

415

In-Situ Sequencing, CRISPR Patents, and Racist Milk Drinkers: February 2017 with Nathan and Laura

416

New Pocket Size Nanopore Device Could Revolutionize Diagnostic and Other Testing

417

By Changing a Basic Lab Step, Acoustic Liquid Transfer Having a Broad Impact

418

Many Biologists Today Don’t Have Enough Computer Science to Use the Databases

419

Cardiologists Love Genomics: Euan Ashley, Stanford

420

Scientists vs Trump: January 2017 with Nathan and Laura

421

Want to Stop Smoking? Start with Epigenetic Biomarker that Tells Doc the Truth

422

When an Exome Test Is Part of the Therapy and Not a Diagnostic: John West on Personalis and Personalized Cancer Vaccines

423

People Told Us It Was Impossible: UCSC’s Mark Akeson on Nanopore Sequencing

424

When Long Reads are Double the Price of Short Reads, Short Reads Are Dead, Says Evan Eichler

425

Genomics in 2016: Nathan and Laura Name Their Top Stories

426

Hank Greely on “The End of Sex" and Other Stuff

427

How to Scale Cancer Genomics, with Marco Marra, UBC

428

What Does the Election Mean for Genomics? November 2016 with Nathan and Laura

429

The Saga Continues: Ethan Perlstein, Indie Scientist, Part 3

430

Biomarker Panel to Predict Type 1 Diabetes

431

Can You Name the World’s Largest Single Disease Research Charity?

432

Why Diversity Is the Only Path Forward: Sarah Tishkoff on African Genomics

433

October 2016 with Nathan and Laura

434

We’re Over Halfway There: Baylor's Richard Gibbs on Clinical Genetics

435

With FDA Guidance on LDTs Still Not Out, What Are Labs Doing?

436

Reference Genome Making Major Strides in Ethnic Diversity, Says Valerie Schneider, NCBI

437

September 2016 with Nathan and Laura

438

Luke Timmerman on His New Biography of Lee Hood

439

How Personalized is Personalized Medicine? Krister Wennerberg on FIMM’s Individualized Systems Medicine

440

Digital PCR Opens Up New Liquid Biopsy Opportunity in Melanoma Treatment: David Polsky, NYU

441

Erica Ramos on Her Pioneering Role as Genetic Counselor for Industry

442

August 2016 with Nathan and Laura

443

A Maniacal Commitment to Science: Peering into Regeneron’s Genetics Center with Jeff Reid

444

The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 2

445

The Days of Miracle and Wonder: Laura Hercher on Genetic Counseling, Part 1

446

A Precision Medicine Platform Comes of Age: Jonathan Hirsch, Syapse

447

FDA’s Liz Mansfield on New NGS Guidances

448

How Is the Brexit Impacting Genomics? with Clare Turnbull and Hadyn Parry

449

It’s Not Really Bulls and Bears: John Carroll on His New Gig, the Brexit, and a New Metaphor for the Market

450

June 2016 with Nathan and Laura: GMO Labeling, Misspelling CRISPR, Sequenom Patent Loss, SmidgIon

451

Know Then Thyself: Kari Stefansson, deCODE genetics

452

Sequenom Patent Loss a Threat to Personalized Medicine, Says Kevin Noonan

453

Bringing Home Some Diagnostics Gold: Brad Gray, NanoString Show How It’s Done

454

Mukherjee Mess-up, the Secret Harvard Meeting, and Success in Gene Therapy: May 2016 with Nathan and Laura

455

When Do We Move to Population Based Cancer Screening for Those with High Genetic Risk? Josh Schiffman, U of U

456

The Solid Future of Liquid Biopsies with Michael Nall, Biocept

457

Genomics Is Oversubscribed, Says Creator of BLAST

458

With 10K Genomes Sequenced, Genomics England in High Gear: Clare Turnbull, Clinical Lead

459

April 2016 with Nathan and Laura: Big Money, More CRISPR Studies, Genomic Superheroes, and a Pot Chaser

460

A Sneak Peek into the Future of Clinical Genomics with Ben Solomon, Inova

461

Preprints and the Future of Science Publishing with Jason Hoyt, PeerJ

462

Flipping Drug Development Upside Down: Niven Narain, BERG Health

463

March 2016 with Nathan and Laura: Genomic Jenga and the Creator, the Anti-Abortion Lobby and Genetic Testing, and Theranos, Again

464

Medicine and the Limits of Science with Michel Accad, MD

465

How Good are Linked Reads? Serge Saxonov, 10X Genomics

466

A Home Run on the First Hit: PacBio’s Jonas Korlach

467

Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level

468

February 2016: Mosquitos, Preprints, and that Rocking White House Summit

469

BioNano Genomics Stakes Out Sequencing Territory as They Discover Lots of De Novo Variants in Reference Genome Projects

470

Is Oxitec Ready to Scale as Governments Seek Options to Control the Zika Virus?

471

Human Genome Turns 15: Mike Hunkapiller

472

January 2016: Landergate, Grail, and Cancer Moonshot

473

Frontiers of Sequencing: Putting Long Reads and Graph Assemblies to Work

474

Why Drugs Are Priced So High and Diagnostics So Low

475

Who Is John Ioannidis?

476

Cancer: Year in Review 2015 with Anna Barker

477

Sci-Fi Author Kim Stanley Robinson Talks Life Science 2015

478

Yes to FDA Regulation of LDTs, But We Need a New Framework, Says David Spetzler

479

Genomics and the Cloud Going Through “a Second Puberty,” says AWS’ Angel Pizarro

480

Hot Biotech Market Neglects Stem Cell Therapies, Says CIRM's Neil Littman

481

The Future of Diagnostics Reimbursement with Bruce Quinn

482

Framingham for the Modern Era: Josie Briggs on the Precision Medicine Initiative

483

Do Alternate Proposals to Regulate LDTs Stand a Chance?

484

Does the Reproducibility Project in Cancer Biology Offer a Model for a New Kind of Science Auditing?

485

After CMS Announcement, Peter Maag and CareDx Fight for Life

486

The Goal Is De Novo Assembly in the Clinic, Says Jim Lupski, Baylor

487

Cliff Reid Says New Supersequencer Leads the Pack for High Throughput Clinical Sequencing

488

Defending the Value of Biotech Innovation in California: Sara Radcliffe, CLSA

489

Long Read Sequencing Dramatically Improves Blood Matching: Steven Marsh, Anthony Nolan Institute

490

The World of DIY Genomics with K T Pickard

491

Sequencing in Space: Chris Mason, Cornell

492

Is the Future of Biology a Return to Chemistry? Carolyn Bertozzi, Stanford

493

Going Beyond the $1,000 Genome with Mark Gerstein

494

Creating the Foundation of Genomics: Marc Salit, NIST

495

Still Unhappy with FDA’s Plan to Regulate LDTs, Professional Lab Groups Go Direct to the Senate

496

A Diagnostic Success Story with Alka Chaubey, Greenwood Genetic Center

497

With Two New Easy-to-Use Sequencing Instruments, Thermo Readies for Primetime in the Clinic

498

Here's Looking at Euclid

499

Is This the Future of Clinical Trials for Cancer? Stanley Hamilton on the NCI’s New MATCH Trial

500

Brian Kennedy and Aubrey de Grey on their Converging Approaches to Aging Research